Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 100
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Non-Hodgkin's Lymphoma (NHL) epidemiology and market outlook for the 7MM.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Non-Hodgkin's Lymphoma (NHL) Understanding and Treatment Algorithm

The market report provides the overview of the Non-Hodgkin's Lymphoma (NHL) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Non-Hodgkin's Lymphoma (NHL) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Non-Hodgkin's Lymphoma (NHL) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Non-Hodgkin's Lymphoma (NHL) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Non-Hodgkin's Lymphoma (NHL) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Non-Hodgkin's Lymphoma (NHL) market.

Non-Hodgkin's Lymphoma (NHL) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Non-Hodgkin's Lymphoma (NHL) Report Insights

- Patient Population in Non-Hodgkin's Lymphoma (NHL)

- Therapeutic Approaches in Non-Hodgkin's Lymphoma (NHL)

- Non-Hodgkin's Lymphoma (NHL) Pipeline Analysis

- Non-Hodgkin's Lymphoma (NHL) Market Size and Trends

- Non-Hodgkin's Lymphoma (NHL) Market Opportunities

- Impact of upcoming Therapies in Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL) Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Non-Hodgkin's Lymphoma (NHL) Report Assessment

- Current Treatment Practices in Non-Hodgkin's Lymphoma (NHL)

- Unmet Needs in Non-Hodgkin's Lymphoma (NHL)

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Non-Hodgkin's Lymphoma (NHL) market

- Organize sales and marketing efforts by identifying the best opportunities for Non-Hodgkin's Lymphoma (NHL) market

- To understand the future market competition in the Non-Hodgkin's Lymphoma (NHL) market.

Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Non-Hodgkin's Lymphoma (NHL) Market Overview at a Glance
2.1. Market Share Distribution of Non-Hodgkin's Lymphoma (NHL) in 2016
2.2. Market Share Distribution of Non-Hodgkin's Lymphoma (NHL) in 2028
3. Disease Background and Overview: Non-Hodgkin's Lymphoma (NHL)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Non-Hodgkin's Lymphoma (NHL) in 7MM
4.3. Total Prevalent Patient Population of Non-Hodgkin's Lymphoma (NHL) in 7MM - By Countries
5. Epidemiology of Non-Hodgkin's Lymphoma (NHL) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.1.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.1.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.1.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.1.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.4.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.4.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.4.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.4.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.5.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.5.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.5.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.5.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.6.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.6.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.6.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.6.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.7.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.7.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.7.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.7.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.8.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.8.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.8.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.8.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL)
5.9.3. Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) *
5.9.4. Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) *
5.9.5. Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL)
5.9.6. Treatable Cases of the Non-Hodgkin's Lymphoma (NHL)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Non-Hodgkin's Lymphoma (NHL)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Non-Hodgkin's Lymphoma (NHL)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Non-Hodgkin's Lymphoma (NHL) : 7MM Market Analysis
12.1. 7MM Market Size of Non-Hodgkin's Lymphoma (NHL)
12.2. 7MM Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL)
12.3. 7MM Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products
13. Non-Hodgkin's Lymphoma (NHL) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in United States
13.1.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in United States
13.1.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in Germany
13.2.1.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in Germany
13.2.1.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in France
13.2.2.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in France
13.2.2.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in Italy
13.2.3.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in Italy
13.2.3.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in Spain
13.2.4.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in Spain
13.2.4.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in United Kingdom
13.2.5.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Non-Hodgkin's Lymphoma (NHL) in Japan
13.3.2. Percentage Share of drugs marketed for Non-Hodgkin's Lymphoma (NHL) in Japan
13.3.3. Market Sales of Non-Hodgkin's Lymphoma (NHL) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in 7MM
Table 2: Total Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Table 6: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Table 7: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Table 12: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Table 15: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Table 16: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Table 17: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Table 22: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Table 27: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Table 31: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Table 32: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Table 37: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 42:7MM- Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 45: United States-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 48: Germany-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 51: France-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 54: Italy-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 57: Spain-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 60:UK-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Table 63: Japan-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Figure 7: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Figure 12: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Figure 16: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Figure 17: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Figure 22: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Figure 27: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Figure 32: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Figure 37: Treatable Cases of the Non-Hodgkin's Lymphoma (NHL) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 42:7MM- Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 45: United States-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 48: Germany-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 51: France-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 54: Italy-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 57: Spain-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 60:UK-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Non-Hodgkin's Lymphoma (NHL) in USD MM (2016-2028)
Figure 63: Japan-Market Share Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Non-Hodgkin's Lymphoma (NHL) by Therapies in USD MM (2016-2028)

  • Global Cancer Immunomodulator Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
  • Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
  • Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125
    According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
  • Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112
    This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
  • Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
  • T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85
    CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
  • Global Kaposi Sarcoma Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107
    Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
  • Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs